939773-60-1

Upstream product

• 62902-66-3 6-(3-chlorophenyl)-2,3-dihydropyridazin-3-one 
• 619-23-8 3-Nitrobenzyl chloride 

Downstream Products

• 939773-54-3 C₂₅H₂₇ClN₄O₄*ClH 
• 1443124-87-5 N¹-(3-((3-(3-chlorophenyl)-6-oxopyridazin-1(6H)-yl)methyl)phenyl)-N⁴,N⁴-diethylpiperidine-1,4-dicarboxamide 

Relevant academic research and scientific papers

Discovery of novel 2,6-disubstituted pyridazinone derivatives as acetylcholinesterase inhibitors

2,6-Disubstituted pyridazinone 4 was identified by HTS as a novel acetylcholinesterase (AChE) inhibitor. Under SAR development, compound 17e stood out as displaying high AChE inhibitory activity and AChE/butyrylcholinesterase (BuChE) selectivity in vitro. Docking studies revealed that 17e might interact with the catalytic active site (CAS) and the peripheral anionic site (PAS) simultaneously. Based on this novel binding information, 6-ortho-tolylamino and N-ethyl-N-isopropylacetamide substituted piperidine were disclosed as new PAS and CAS binders.

Pyridiazinone Derivatives for the Treatment of Tumours

Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours